GSEA was further implemented to decipher the mechanism of MTHFD2 functioning in UCB, the result of which suggested that numerous signaling pathways were enriched in MTHFD2 high expression group, including NF-κB activation, mitotic phases, JAK/STAT, cancer immunotherapy by PD1 blockade, signaling pathway by EGFR in cancer, MAPK family signaling cascades, PI3K/AKT/mTOR, and senescence and autophagy in cancer pathways. The gene discussed is MTOR; the disease is cancer.